A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
- Conditions
- Relapsed Refractory Non Hodgkin Lymphomas with CD30 ExpressionMedDRA version: 19.0Level: HLTClassification code 10029606Term: Non-Hodgkin's lymphomas transformed recurrentSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2015-003286-28-FR
- Lead Sponsor
- Bristol-Myers Squibb International Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Relapsed/refractory Diffuse Large B
Cell Lymphoma (DLBCL),
relapsed/refractory Peripheral T
Cell Lymphoma (PTCL) (all subtypes
excluding Anaplastic Large Cell
Lymphoma) and relapsed/refractory
Cutaneous T Cell Lymphoma (CTCL)
Mycosis Fungoides/Sezary Syndrome (MF/SS)
Expression of CD30
Subjects must be 18 years or older
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 60
Exclusion Criteria
Known central nervous system (CNS)
lymphomas; Active
cerebral/meningeal disease related
to the underlying malignancy
Active, known, or suspected autoimmune disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method